Company intelligence / Profile preview

Synthecon

Houston, Texas, United States

Ownership: Private
Employees: ~27
Development stage: Other

Overview

Synthecon's RCCS technology is highly recognized in biomedical research for enabling physiologically relevant 3D cell culture; there are no clinical results since Synthecon's technology is for research, not clinical development

Modalities: Device (bioreactor systems)Scaffold-free cell culture technologies
Industry: Non-Drug Biotech

Partnerships

National Science Foundation (funding partnership)

Beyond the preview

Go deeper on Synthecon.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Synthecon.

Explore the full profile